Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
Hönle increases profit in Q3 2026 despite only slight revenue growth
Hönle reports a Q3 2026 revenue increase of 4.9% to €23.7m and an EBITDA of €1.7m versus €0.5m a year earlier, lifting the margin to 7.3%. In the nine-month period revenue remained stable at €69m, while EBITDA rose 26% to €4.5m. Improved cost discipline, a more favorable product mix and lower material costs contributed to the margin improvement, while the curing segment remains under pressure. Management confirmed the full-year guidance (revenue €92–95m, EBITDA €5–6m) and expects curing to grow again in fiscal 2026/2027. » More on de.investing.com
Dr Hönle executive expands stake and buys 56,680 shares
On 9 December 2025 Dr. Richter Vermögens- und Beteiligungsverwaltung GmbH (board member) acquired 56,680 Dr Hönle shares at €6.80 each; the trade was reported on 10 December 2025. The announcement temporarily pushed the price higher in FSE trading; the stock closed at €6.82 (+2.10%). The executive had previously bought 27,008 shares at €16.66 each on 22 February 2024. » More on finanzen.net
Dr Hönle expects significant improvement in quarterly results
Dr Hönle will present figures for the past quarter on August 7, 2025. Analysts forecast earnings per share of 0.050 EUR, compared to a loss in the same quarter last year, and expect revenue to rise to 26.3 million EUR. A significant improvement in results is also anticipated for the current fiscal year. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 23.71m | 4.71% |
| Gross profit | 3.4m | 76.09% |
| Net profit | -224k | 75.30% |
| EBITDA | 1.98m | 272.05% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €40.24m |
Number of shares | 5.51m |
52-week high/low | €23.60 - €6.70 |
| Dividends | No |
Beta | 1.49 |
P/E ratio | -15.31 |
PEG ratio | -0.22 |
P/B ratio | 0.58 |
P/S ratio | 0.48 |
Company profile
Dr. Hönle AG supplies industrial UV technologies and systems in Germany and internationally. The company operates through three segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives segment provides industrial adhesives for applications, such as consumer electronics, medical technology, optics and opto electronics, automotive, and glass processing. The Equipment & Systems segment engages in the drying of inks and coatings, curing of adhesives and plastics, disinfecting surfaces, and solar simulation. The Glass & Lamps segment offers quartz glass tubing and rods for the lamp, automotive, semiconductor, and fibre cable industries, as well as lamps for water disinfection, and the drying of coatings and adhesives. The company was founded in 1976 and is headquartered in Munich, Germany.
| Name | Dr. Hönle |
| CEO | Franz Richter |
| Headquarters | Gilching,
bv Germany |
| Website | |
| Sector | Information Technology |
| Industry | Technology Hardware, Storage & Peripherals |
| IPO | 24/01/2001 |
| Employees | 567 |
Ticker symbols
| Exchange | Symbol |
|---|---|
XETRA | HNL.DE |
London Stock Exchange | 0O27.L |
Frankfurt | HNL.F |
Düsseldorf | HNL.DU |
Hamburg | HNL.HM |
London | 0O27.L |
SIX | HNL.SW |
München | HNL.MU |